AX-2024-004825 · Tirzepatide · SWB lot SWB-2311-B7511

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	96.97	% area	≥ 97.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	3.03	% area	≤ 3.0	FAIL
Largest single impurity	RP-HPLC — [D-Aib13]-diastereomer	1.74	% area	≤ 1.00	FAIL
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	84.79	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	82.22	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	16.93	mg	15 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	13.920	mg	15 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	92.8	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	7.38	%	≤ 8.0	PASS
Counter-ion (TFA)	anion-exchange ion chromatography	7.15	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.68	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.38	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.52	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	18.53	min	18.64 ± 0.45 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.10	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	46,323	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Aib13]-diastereomer	0.50	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 46,323, and skew follows the reported asymmetry factor of 1.10. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 1.74 % impurity against a 96.97 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Tirzepatide — main peak	18.53	4,713,043	96.97	—
2	[D-Aib13]-diastereomer	18.35	84,569	1.74	0.000
3	truncated (3-39)	17.15	38,396	0.79	-222.112
4	des-Aib2 analogue	18.20	12,637	0.26	-85.053
5	C20 diacid mono-amide	20.04	6,804	0.14	+0.984
6	Met(O) sulfoxide (+16 Da)	17.84	2,916	0.06	+15.995
7	tirzepatide dimer	22.24	1,944	0.04	+4810.410
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	7.38
Counter-ion (TFA)	ion chromatography	7.15
Residual solvent + inorganic residue	estimated	0.68
Total peptide content	by difference	84.79
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	97.41	96.97	divergence +0.10 pp vs batch median
Total impurities (% area)	2.59	3.03
Largest single impurity (% area)	not stated	1.74
Water (%)	5.5	7.38
Counter-ion (%)	not stated	7.15
Peptide content (%w/w)	96.2	84.79
Endotoxin (EU/mg)	0.64	0.38
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 16 d) → laboratory (hand-carried, 7 d) → assay.
Assay date: 24 May 2024
Submitted to the index: 28 May 2024
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

uncertainty_budget28 May 2024

The gap between 96.97 % and the class specification should be read against an expanded uncertainty of roughly ±0.5 pp. A shortfall inside that band is not a finding; a shortfall well outside it is.

survivor_lots28 May 2024

Lots get submitted for two reasons: somebody submits everything, or somebody was surprised. The second reason over-represents results in this band across the whole index, and the aggregate caveat exists for it.

chain_custody28 May 2024

A retail vial at 96.97 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.

Section 7

Related records

Same batch — lot SWB-2311-B7511 n=8

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2024-004821	SWB-2311-B7511	Janoshik	2024-Q2	97.68	7.28	99.5	Supplier-supplied	PASS
AX-2024-004822	SWB-2311-B7511	Nordanalyt	2024-Q2	97.33	6.65	94.8	Buyer-sourced	PASS
AX-2024-004823	SWB-2311-B7511	Janoshik	2024-Q2	97.41	7.67	95.7	Buyer-sourced	PASS
AX-2024-004824	SWB-2311-B7511	PeptideMeter	2024-Q2	97.29	7.27	98.4	Buyer-sourced	PASS
AX-2024-004826	SWB-2311-B7511	PeptideMeter	2024-Q2	96.85	6.26	—	Buyer-sourced	FAIL
AX-2024-004827	SWB-2311-B7511	Janoshik	2024-Q2	98.06	6.53	94.6	Supplier-supplied	PASS
AX-2024-004828	SWB-2311-B7511	Janoshik	2024-Q2	97.29	6.98	—	Supplier-supplied	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Tirzepatide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-043288	CPC	CPC-2607-L1516	Janoshik	2026-Q3	96.89	5.11	101.1	Laboratory-retained	FAIL
AX-2026-041610	FGP	FGP-2603-L7753	Janoshik	2026-Q3	98.81	2.45	101.0	Buyer-sourced	PASS
AX-2026-041974	AMB	AMB-2603-C5112	Nordanalyt	2026-Q3	98.20	3.41	—	Buyer-sourced	PASS
AX-2026-041975	AMB	AMB-2603-C5112	Medutest	2026-Q3	97.88	3.45	106.9	Laboratory-retained	PASS
AX-2026-041609	FGP	FGP-2603-L7753	Janoshik	2026-Q3	98.52	2.00	98.0	Buyer-sourced	PASS
AX-2026-041978	AMB	AMB-2603-C5112	Janoshik	2026-Q3	97.94	3.57	103.0	Buyer-sourced	PASS
AX-2026-041982	AMB	AMB-2603-C5112	Janoshik	2026-Q3	97.60	4.46	—	Buyer-sourced	PASS
AX-2026-043286	CPC	CPC-2607-L1516	Kestrel	2026-Q3	98.20	4.56	—	Buyer-sourced	PASS

Other recent SWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042637	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.37	4.26	102.9	Buyer-sourced	PASS
AX-2026-042645	Semaglutide	SWB-2602-X7905	Medutest	2026-Q3	98.48	4.52	95.2	Buyer-sourced	PASS
AX-2026-042642	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	97.96	4.48	90.8	Buyer-sourced	PASS
AX-2026-042640	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	98.55	4.29	—	Buyer-sourced	PASS
AX-2026-042638	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.74	3.65	—	Buyer-sourced	PASS
AX-2026-042639	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.77	4.21	—	Supplier-supplied	PASS
AX-2026-042641	Semaglutide	SWB-2602-X7905	Janoshik	2026-Q3	98.86	4.48	99.1	Buyer-sourced	PASS
AX-2026-042644	Semaglutide	SWB-2602-X7905	PeptideMeter	2026-Q3	98.76	3.57	97.7	Buyer-sourced	PASS